Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | PTPRZ1 | P23471 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | AIMP2 | Q13155 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16994745 | 0.86 | KMT2A (0.59) | LMNAPOLBPTPRZ1SMN1; SMN2HPGD | |
| SCHEMBL21178388 | 0.83 | PTPRZ1 (0.46) | LMNAPOLBPTPRZ1SMN1; SMN2HPGD | |
| SCHEMBL826024 | 0.80 | HPGD (0.51) | LMNASMN1; SMN2HPGDKMT2AKDM4E | |
| SCHEMBL4475119 | 0.79 | LMNA (0.64) | LMNAPOLBSMN1; SMN2HPGDRAB9A | |
| SCHEMBL15610864 | 0.78 | KMT2A (0.54) | LMNAPOLBSMN1; SMN2KMT2AKDM4E | |
| SCHEMBL20725429 | 0.77 | RAB9A (0.55) | LMNAPOLBSMN1; SMN2KMT2ARAB9A | |
| SCHEMBL17298901 | 0.76 | LMNA (0.44) | LMNAPOLBPTPRZ1SMN1; SMN2KMT2A | |
| SCHEMBL12471200 | 0.76 | TRPV1 (0.48) | LMNAPOLBSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL17359285 | 0.74 | HPGD (0.54) | LMNASMN1; SMN2HPGDKDM4ECYP1A2 | |
| SCHEMBL26748615 | 0.74 | PLK1 (0.50) | LMNAPOLBSMN1; SMN2HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108566-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108566-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | JAK2, JAK1, NADK | LMNA 2451/4885POLB 2890/4885PTPRZ1 1615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.